Version 1
: Received: 11 February 2019 / Approved: 13 February 2019 / Online: 13 February 2019 (15:44:08 CET)
Version 2
: Received: 23 May 2019 / Approved: 24 May 2019 / Online: 24 May 2019 (12:49:58 CEST)
Version 3
: Received: 20 February 2020 / Approved: 21 February 2020 / Online: 21 February 2020 (06:57:33 CET)
Version 4
: Received: 28 February 2022 / Approved: 1 March 2022 / Online: 1 March 2022 (12:58:34 CET)
Version 5
: Received: 18 July 2023 / Approved: 19 July 2023 / Online: 19 July 2023 (12:57:15 CEST)
Version 6
: Received: 20 September 2023 / Approved: 21 September 2023 / Online: 22 September 2023 (11:07:35 CEST)
How to cite:
Padilla, C.A.; Álvarez, M.J.; Campo, E.; Severiche, J.G.; Combariza, A.F. The Future of Leishmaniasis Treatment: Protein Targets and Beyond. Preprints2019, 2019020122. https://doi.org/10.20944/preprints201902.0122.v5
Padilla, C.A.; Álvarez, M.J.; Campo, E.; Severiche, J.G.; Combariza, A.F. The Future of Leishmaniasis Treatment: Protein Targets and Beyond. Preprints 2019, 2019020122. https://doi.org/10.20944/preprints201902.0122.v5
Padilla, C.A.; Álvarez, M.J.; Campo, E.; Severiche, J.G.; Combariza, A.F. The Future of Leishmaniasis Treatment: Protein Targets and Beyond. Preprints2019, 2019020122. https://doi.org/10.20944/preprints201902.0122.v5
APA Style
Padilla, C.A., Álvarez, M.J., Campo, E., Severiche, J.G., & Combariza, A.F. (2023). The Future of Leishmaniasis Treatment: Protein Targets and Beyond. Preprints. https://doi.org/10.20944/preprints201902.0122.v5
Chicago/Turabian Style
Padilla, C.A., José G. Severiche and Aldo F. Combariza. 2023 "The Future of Leishmaniasis Treatment: Protein Targets and Beyond" Preprints. https://doi.org/10.20944/preprints201902.0122.v5
Abstract
This review summarizes up-to-date research on Leishmania protein structures, extracted primarily from the Protein Data Bank (PDB), that are involved in metabolic pathways of the parasite causing \textit{Leishmania}. Additionally, we examine current advancements in identifying and developing bioactive chemical agents to treat this largely neglected tropical disease. We examined experimental data from \textit{in vitro}, \textit{in vivo}, or \textit{in silico} sources, classifying the information into four categories: a) vector taxonomy and geographical distribution; b) parasite taxonomy and geographical distribution; c) enzymatic functions of proteins involved in parasite/host interactions across developmental stages (e.g. oxidoreductases, transferases, hydrolases, lyases, isomerases, ligases, and cytokines); and d) standard and experimental treatments using bioactive chemical compounds. Our goal is to provide a reference framework for research focused on elucidating interaction mechanisms and ligand-protein activation/inactivation processes related specifically to \textit{Leishmania} infections. We therefore highlight enzymes known to participate in biochemical pathways triggered during Leishmania infection episodes. This review summarizes current knowledge to inform and guide future discovery efforts targeting proteins and pathways for improved \textit{Leishmania} disease management.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
.png)
Commenter: Aldo Combariza
Commenter's Conflict of Interests: Author
2. Author list
3. Abstract
4. An additional Section
5. Update of references and graphs
6. Format